Clinical Trial Update: Twelve vs 24 Months of Dual Antiplatelet Therapy in Patients With Coronary Revascularization for In-stent Restenosis [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update compares 12 versus 24 months of dual antiplatelet therapy in patients who have undergone coronary revascularization for in-stent…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• In-stent Restenosis
• Ischemic Heart Disease

Snippet

Sponsor: Beijing Anzhen Hospital | Conditions: Percutaneous Coronary Intervention | Phase 4 | Status: UNKNOWN